WHRY Launches Studies on Endometrial Cancer, Addiction to Opioids, and Stroke
While continuing to focus on the impacts of COVID-19, the center has enlarged its research portfolio to include new projects on the prevention of endometrial cancer in a growing cohort of women at high risk, non-opioid pain management following a cesarean section for women with opioid use disorder who are in recovery, and sex differences in stroke.
WHRY Funds Studies on Stroke, Endometrial Cancer, and Addiction to Opioids
Women’s Health Research at Yale today announced funding for three studies investigating sex differences in stroke, endometrial cancer, and alternate pain relief for women recovering from past opioid use who are giving birth via cesarean section.
“Complete Academic Physician” Dr. Karl Insogna Retires From Clinical Duties
During his childhood in Wolcott, Conn., Karl Insogna’s parents instilled in him a few life lessons. Insogna, MD, FACP, Ensign Professor of Medicine (Endocrinology); director, Yale Bone Center; and associate director, Yale Center for X-Linked Hypophosphatemia; was taught to strive to leave the world a better place than you found it, and to do something to help others.
Welcome New Staff, Postdocs, Postgrads, and Clinical Fellows in the Section of Endocrinology and Metabolism (September 2023)
The Section of Endocrinology and Metabolism is pleased to welcome the following new staff, postdoctoral associates, clinical fellows, and postgraduate fellows and associates.
Introducing the Internal Medicine 2021-2022 Annual Report
In the new report, there are updates from our clinical programs, research endeavors, our work on diversity, equity, and inclusion, and educational programs. Our faculty members were honored for their educational excellence. Research initiatives at Yale received applause on the national and international stages. This book highlights all that we have accomplished together this past year…
3 Factors Keeping Americans From New Weight-Loss Drugs
The shifts in attitude about obesity can also be seen in the KFF survey, said Dr. Ania Jastreboff, an endocrinologist and obesity-medicine specialist at Yale University and a consultant for the makers of the new drugs. After decades of hearing that losing weight was just a matter of exerting willpower, most of the public is intensely interested in medical treatments.Source: The New York Times
In Memoriam: Robert “Bob” S. Sherwin, MD
Robert “Bob” S. Sherwin, MD, the inaugural director of YCCI, passed away on March 31 at Yale-New Haven Hospital after a long illness. He was 80 years old. Dr. Sherwin, a world-renowned academic diabetologist, led YCCI through a remarkable period of growth, and all of those who worked with him will remember his kindness, guidance, and wisdom. Together they mourn the loss of a leader whose inspiring vision will continue to serve as a beacon for the growth of clinical and translation research at Yale, and beyond, for years to come.
Are Ozempic and Wegovy Safe? All About the Diabetes and Obesity Drugs
PEOPLE spoke with Ania Jastreboff M.D., PhD., an obesity medicine physician scientist at Yale University to better understand the drugs and correct common misconceptions about obesity By Sheila Cosgrove Baylis Published on January 24, 2023 02:28 PMSource: People
Yale’s Endocrine Neoplasia Program Is Flourishing
The Yale Multidisciplinary Endocrine Neoplasia Clinic has been treating benign and malignant diseases of the thyroid, parathyroid, adrenal, and pituitary glands since 2013. The program is a collaboration between the Department of Internal Medicine’s Section of Endocrinology & Metabolism and Yale Cancer Center and Smilow Cancer Hospital.
DELIVER: Dapagliflozin cuts risk for worsening HF in adults with, without type 2 diabetes
Dapagliflozin reduces risk for worsening heart failure and cardiovascular death in adults with heart failure with mildly reduced or preserved ejection fraction, regardless of baseline HbA1c, according to findings from the DELIVER trial.Source: Healio
High liver fat associated with impaired glucose, type 2 diabetes in pediatric obesity
Children with obesity and a high level of liver fat content are more likely to have impaired glucose tolerance, prediabetes and type 2 diabetes compared with those with normal liver fat content, according to Sonia Caprio, MD.Source: Healio
Endocrine Society Educates Congress About the Science of PFAS Exposure
The Endocrine Society hosted a congressional briefing on November 6th, 2019, on the latest science with policy makers on how federally funded research is helping to understand and address the health effects of exposure to per- and polyfluoroalkyl substances, also known as PFAS. Expert scientists gathered to discuss widespread contamination issues and diverse health effects attributed to PFAS exposure. Zeyan Liew, PhD, MPH, from the Yale School of Public Health shared his research exploring the effects of PFAS on maternal thyroid function and neurodevelopmental outcomes in exposed children.Source: Endocrine News
MFS2 Regulation Controls Phosphate Excretion, Renal Stone Formation, Study Finds
A high phosphate diet caused stones within the Malpighian renal tubules and resulted in reduced lifespan of fruit flies, says new study led by Yale School of Medicine’s Clemens Bergwitz, MD, associate professor of medicine (endocrinology).